Literature DB >> 16011894

Non-nicotine pharmacotherapies for smoking cessation.

H McRobbie1, M Lee, Z Juniper.   

Abstract

International chronic obstructive pulmonary disease guidelines recommend that smokers be strongly advised to quit, and should be offered help in doing so. The most effective smoking-cessation interventions combine behavioural support with pharmacotherapies. For smokers who do not wish to use nicotine replacement treatments, bupropion is a safe and effective non-nicotine alternative first-line treatment. Nortriptyline and clonidine have demonstrated efficacy in aiding smoking cessation, but are regarded as second-line therapies. A number of other non-nicotine treatments show promise, but more data are required before these can be recommended in assisting smokers to stop.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16011894     DOI: 10.1016/j.rmed.2005.05.016

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  5 in total

Review 1.  Rodent models for nicotine withdrawal.

Authors:  Ranjithkumar Chellian; Azin Behnood-Rod; Dawn M Bruijnzeel; Ryann Wilson; Vijayapandi Pandy; Adriaan W Bruijnzeel
Journal:  J Psychopharmacol       Date:  2021-04-22       Impact factor: 4.562

2.  Antidepressants for smoking cessation.

Authors:  Seth Howes; Jamie Hartmann-Boyce; Jonathan Livingstone-Banks; Bosun Hong; Nicola Lindson
Journal:  Cochrane Database Syst Rev       Date:  2020-04-22

Review 3.  Antidepressants for smoking cessation.

Authors:  John R Hughes; Lindsay F Stead; Jamie Hartmann-Boyce; Kate Cahill; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2014-01-08

Review 4.  The use of bupropion SR in cigarette smoking cessation.

Authors:  Scott Wilkes
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

5.  Need for medication to complement catecholamines in smoking cessation of hardcore smokers.

Authors:  Atsuko Kawai; Masatake Kurita; Satoshi Nishino; Eishin Hirata; Tadahiro Sato; Yoshiro Okubo
Journal:  Neuropsychiatr Dis Treat       Date:  2017-09-18       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.